New Biomarkers for Selecting the Best Therapy Regimens in Metastatic Castration-Resistant Prostate Cancer

被引：10
作者：
Heidegger, Isabel [1 ]
Heidenreich, Axel [1 ]
Pfister, David [1 ]
机构：
[1] Univ Hosp Cologne, Dept Urol, Kerpener Str 62, D-50937 Cologne, Germany
来源：
TARGETED ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
CIRCULATING TUMOR-CELLS; OVERCOMES ENZALUTAMIDE RESISTANCE; PROGRESSION-FREE SURVIVAL; RECEPTOR SPLICE VARIANTS; ACETATE PLUS PREDNISONE; ABIRATERONE ACETATE; ANDROGEN RECEPTOR; DOCETAXEL CHEMOTHERAPY; SIPULEUCEL-T; PREDICTIVE BIOMARKER;
D O I：
10.1007/s11523-016-0461-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Prostate cancer is the most common cancer in men. In recent years, several new targeted therapeutic agents for the treatment of metastatic castration resistant prostate cancer (mCRPC) have been developed. These include androgen receptor targeting agents, new taxanes, radium-223, and immunotherapies. In this short review, we provide a summary of clinical and preclinical biomarkers for each of these new treatment strategies, also including new markers currently presented in conference papers only. Moreover, we address the role of these biomarkers in clinical routine with the aim to select best-personalized treatment strategies for patients. Finally, we provide a decision tree for selecting the proper therapy for patients with mCRPC according to the discussed biomarkers.
引用
收藏
页码：37 / 45
页数：9
相关论文
共 74 条
  • [1] Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer
    Angelergues, Antoine
    Maillet, Denis
    Flechon, Aude
    Ozguroglu, Mustafa
    Mercier, Florence
    Guillot, Aline
    Le Moulec, Sylvestre
    Gravis, Gwenaelle
    Beuzeboc, Philippe
    Massard, Christophe
    Fizazi, Karim
    Rouge, Thibault de La Motte
    Delanoy, Nicolas
    Elaidi, Reza-Thierry
    Oudard, Stephane
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 (09) : 1602 - 1609
  • [2] Development of Castration Resistant Prostate Cancer can be Predicted by a DNA Hypermethylation Profile
    Angulo, Javier C.
    Andres, Guillermo
    Ashour, Nadia
    Sanchez-Chapado, Manuel
    Lopez, Jose I.
    Ropero, Santiago
    [J]. JOURNAL OF UROLOGY, 2016, 195 (03) : 619 - 626
  • [3] Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
    Antonarakis, Emmanuel S.
    Lu, Changxue
    Luber, Brandon
    Wang, Hao
    Chen, Yan
    Nakazawa, Mary
    Nadal, Rosa
    Paller, Channing J.
    Denmeade, Samuel R.
    Carducci, Michael A.
    Eisenberger, Mario A.
    Luo, Jun
    [J]. JAMA ONCOLOGY, 2015, 1 (05) : 582 - 591
  • [4] Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
    Arora, Vivek K.
    Schenkein, Emily
    Murali, Rajmohan
    Subudhi, Sumit K.
    Wongvipat, John
    Balbas, Minna D.
    Shah, Neel
    Cai, Ling
    Efstathiou, Eleni
    Logothetis, Chris
    Zheng, Deyou
    Sawyers, Charles L.
    [J]. CELL, 2013, 155 (06) : 1309 - 1322
  • [5] Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate
    Attard, Gerhardt
    de Bono, Johann S.
    Logothetis, Christopher J.
    Fizazi, Karim
    Mukherjee, Som D.
    Joshuas, Anthony M.
    Schrijvers, Dirk
    van den Eertwegh, Alfons J. M.
    Li, Weimin
    Molina, Arturo
    Griffin, Thomas W.
    Kheoh, Thian
    Ricci, Deborah S.
    Zelinsky, Kathy
    Rathkopf, Dana E.
    Scher, Howard I.
    Ryan, Charles J.
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (07) : 1621 - 1627
  • [6] Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
    Azad, Arun A.
    Volik, Stanislav V.
    Wyatt, Alexander W.
    Haegert, Anne
    Le Bihan, Stephane
    Bell, Robert H.
    Anderson, Shawn A.
    McConeghy, Brian
    Shukin, Robert
    Bazov, Jenny
    Youngren, Jack
    Paris, Pamela
    Thomas, George
    Small, Eric J.
    Wang, Yuzhuo
    Gleave, Martin E.
    Collins, Colin C.
    Chi, Kim N.
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (10) : 2315 - 2324
  • [7] Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095
  • [8] PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
    Bishop, Jennifer L.
    Sio, Alexander
    Angeles, Arkhjamil
    Roberts, Morgan E.
    Azad, Arun A.
    Chi, Kim N.
    Zoubeidi, Amina
    [J]. ONCOTARGET, 2015, 6 (01) : 234 - 242
  • [9] The androgen/androgen receptor axis in prostate cancer
    Bluemn, Eric G.
    Nelson, Peter S.
    [J]. CURRENT OPINION IN ONCOLOGY, 2012, 24 (03) : 251 - 257
  • [10] Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone
    Burgio, Salvatore Luca
    Conteduca, Vincenza
    Menna, Cecilia
    Carretta, Elisa
    Rossi, Lorena
    Bianchi, Emanuela
    Kopf, Barbara
    Fabbri, Francesca
    Amadori, Dino
    De Giorgi, Ugo
    [J]. ENDOCRINE-RELATED CANCER, 2014, 21 (03) : 487 - 493
12345678